RiverPark Advisors LLC Raises Stock Position in Boston Scientific Corporation $BSX

RiverPark Advisors LLC lifted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 216.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 903 shares of the medical equipment provider’s stock after acquiring an additional 618 shares during the quarter. RiverPark Advisors LLC’s holdings in Boston Scientific were worth $97,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in BSX. 1248 Management LLC acquired a new position in shares of Boston Scientific during the first quarter worth about $26,000. Y.D. More Investments Ltd purchased a new stake in shares of Boston Scientific during the 1st quarter valued at about $27,000. Sound Income Strategies LLC lifted its position in Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares in the last quarter. Princeton Global Asset Management LLC purchased a new position in Boston Scientific in the 2nd quarter worth approximately $32,000. Finally, Oliver Lagore Vanvalin Investment Group acquired a new stake in Boston Scientific in the second quarter valued at approximately $37,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,739,678.74. This trade represents a 21.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares in the company, valued at $2,371,889.52. The trade was a 34.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 175,782 shares of company stock worth $17,742,314 over the last quarter. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $101.37 on Wednesday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm’s 50-day moving average price is $98.98 and its two-hundred day moving average price is $102.30. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50. The stock has a market capitalization of $150.27 billion, a P/E ratio of 54.21, a P/E/G ratio of 2.02 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The business had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. During the same period in the prior year, the firm earned $0.63 EPS. The business’s quarterly revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, sell-side analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Truist Financial boosted their target price on shares of Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Canaccord Genuity Group restated a “buy” rating and set a $132.00 target price on shares of Boston Scientific in a research note on Thursday, October 23rd. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, October 8th. Wells Fargo & Company increased their price target on Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Finally, Leerink Partners raised their price objective on Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, Boston Scientific currently has a consensus rating of “Buy” and an average price target of $123.77.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.